OncoSec Medical IncのIPO年
OncoSec Medical IncのIPO年は何ですか。
OncoSec Medical IncのIPO年は2011です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
NASDAQのセクタHealth CareにおけるIPO年の企業と比べるOncoSec Medical Inc
OncoSec Medical Incは何をしますか。
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Incと類似のipo年
- Goldman Sachs Mutual Fund - Goldman Sachs Nifty Exchange Traded SchemeのIPO年は2010です。
- Software Effective SolutionsのIPO年は2010です。
- GINSMSのIPO年は2010です。
- Photonike Capital SAのIPO年は2010です。
- Parabolic DrugsのIPO年は2010です。
- West Kirkland MiningのIPO年は2010です。
- OncoSec Medical IncのIPO年は2011です。
- Omineca Mining and MetalsのIPO年は2012です。
- iShares Asia Trust - iShares Core CSI 300 Index ETFのIPO年は2012です。
- Wendy`s CoのIPO年は2012です。
- UnisysのIPO年は2012です。
- Christopher & BanksのIPO年は2012です。
- WellesleyのIPO年は2012です。